Interleukin Inhibitors Market Outlook 2031
The global interleukin inhibitors market size was valued at USD 39.32 Billion in 2022 and is anticipated to reach USD 166.58 Billion by 2031, expanding at a CAGR of 17.4% during the forecast period, 2023–2031. Interleukin (IL) is a group of cytokines which are synthesized by macrophages, monocytes, lymphocytes, and other cells.
Interleukin regulate cell motility, cell growth, and cell differentiation. Inside the body there are total fifteen different types of interleukin are present. Interleukin inhibitors are immunosuppressive agents which prevent the action of interleukins. IL inhibitors are used in many conditions such as arthritis (psoriatic and rheumatoid), ankylosing spondylitis, systematic sclerosis, gout, psoriasis, asthma, and eczema.
There is a substantial paradigm shift in the autoimmune diseases treatment over the last few decades. The inclination toward targeted therapies is increasing because of improvement in safety and efficiency of profiles. Patent expiry and raised acceptance of biosimilar in Tumor Necrosis Factor (TNF) inhibitors has increased the market growth. Launching of new products are aided the market growth.
For instance, AbbVie, Inc., in 2019, launched Skyrizi (risankizumab-rzaa) for plaque psoriasis treatment. Also, in 2018, Ilumya (tildrakizumab-asmn) was launched by Sun Pharmaceutical Industries Inc. for moderate-to-severe plaque psoriasis.
Due to upcoming launches of late-stage pipeline candidates the demand of interleukin inhibitors is increasing. Expansion of labels of marketed products, for example, Dupixent for atopic dermatitis and Actemra for juvenile idiopathic arthritis are estimated to boost the penetration. Also, ongoing clinical trials are helping IL inhibitors market with their positive outcomes.
Interleukin Inhibitors Market Trends, Drivers, Restraints, and Opportunities
- Growing awareness about benefits of interleukin inhibitors among physicians and consumers is major factor responsible for the market expansion during the forecast period.
- Increasing favorable initiatives and programs by government for promoting usage of interleukin inhibitors and accessibility to strong pipeline of products are projected to drive the market growth.
- Rising prevalence of autoimmune disorders and other inflammatory diseases and rising number of investigational drugs are anticipated to fuel the growth of the market.
- Increasing FDA approvals for therapies and novel drugs for treatment of chronic inflammatory disease is expected to propel the market growth in coming years.
- Growing presence of targeted therapies because of its efficiency and safety is estimated to drive the market growth during the forecast period.
- High cost of utilization and adoption of treatment in different disease application is major factor that can hamper the market growth.
- Strict regulations and guidelines, and side effects related to this treatment are projected to impede the market growth over the forecast period.
Scope of Interleukin Inhibitors Market Report
The report on the global interleukin inhibitors market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Interleukin Inhibitors Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Applications (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, and Others), Types (IL-17, IL-23, IL-1, IL-5, IL-6, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Johnson & Johnson Services, Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., AstraZeneca, Bausch Health, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., and Teva Pharmaceuticals Industries, Ltd.
Interleukin Inhibitors Market Segment Insights
Applications Segment Analysis
Based on applications, the interleukin inhibitors market is divided into psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, and others. The psoriasis segment is expected to hold a key share of the market during the forecast period due to strong performances of Stelara, Cosentyx, and Taltz. Favorable reimbursement policies, growing prevalence of diseases, and increasing awareness among consumers are expected to fuel the segment growth.
On the other hand, the psoriatic arthritis segment is anticipated to expand at a rapid pace during the forecast period. Due to upcoming launches of late-stage pipeline products and expansion of labels of existing products specified for Crohn’s disease, ulcerative colitis, and arthritis are major factors responsible for the market growth.
Types Segment Analysis
On the basis of types, the interleukin inhibitors market is segmented into IL-17, IL-23, IL-1, IL-5, IL-6, and others. The IL-23 segment dominated the market share and is expected to account for a key share of the market in the coming years due to new entrants and usage of blockbuster drug Stelara.
Also, there are other drugs which are added, such as Tremfya in 2017, Ilumya in 2018, and Skyrizi in 2019. Still Stelara is generating largest revenue in spite of its patent expiry in 2023.
However, the IL-17 segment is anticipated to expand at a rapid pace during the forecast period owing to increase in sales of Cosentyx and Taltz. In 2017, a third year of launch, Cosentyx became a blockbuster drug. Launch of Siliq and awaiting approval of bimekizumab are projected to drive the segment growth.
Interleukin Inhibitors Market Regional Analysis
On the basis of regions, the interleukin inhibitors market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period.
The regional market growth can be attributed to increasing commercial sales of interleukin inhibitors in the U.S. In addition to this, there are some other factors responsible for the regional growth are rise in expenditure of healthcare, local presence of major market players, and favorable government initiatives.
On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to economic development, rise in disposable income, growing awareness among consumers, and improvement in infrastructure of healthcare. Developing countries including India, China, and South Korea are projected to boost the segment growth.
The global interleukin inhibitors market has been segmented on the basis of
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Inflammatory Bowel Disease (IBD)
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Johnson & Johnson Services, Inc.
- Novartis AG
- AbbVie Inc.
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Bausch Health
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc.
- Teva Pharmaceuticals Industries, Ltd.
Key players competing in the interleukin inhibitors market include Johnson & Johnson Services, Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., AstraZeneca, Bausch Health, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., and Teva Pharmaceuticals Industries, Ltd.
Major market players are focusing on several business strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, Eli Lilly and Company is involved in the development of Mirikizumab which is an IL-23 product. It is under phase 3 trial and specified for ulcerative colitis and psoriasis.